1 September 2024

Appendix 4C - Quarterly Cashflow Report

Melbourne, Australia:  Starpharma (ASX: SPL; OCTQX: SPHRY) today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 December 2011.

The cash balance at 31 December 2011 was $49m, which includes proceeds of $35m (before costs) from the successful capital raising conducted in November 2011.  Total operating and investing cash outflow for the quarter was $1.8m.

These funds are being applied to accelerating and completing both VivaGel® Bacterial Vaginosis Phase 3 programs (Treatment, and Prevention of Recurrence) supporting an NDA filing and commercial licence, as well as advancing the Company’s drug delivery and agrochemical programs.

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 123kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.